HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01768247|
Recruitment Status : Unknown
Verified January 2013 by Papanikolaou Evangelos, Universitair Ziekenhuis Brussel.
Recruitment status was: Active, not recruiting
First Posted : January 15, 2013
Last Update Posted : January 17, 2013
A thin endometrium is one of the most difficult problems encountered in assisted reproduction every day practice Regarding the proliferative phase, several ways of treatment have been undertaken to circumvent thin endometrium trying to increase thickness with questionable results.
The objective of the current study will be whether a daily dose of 150 IU (international units) of human chorionic gonadotropin (HCG) for seven days concomitant with estrogen administration in estrogen replacement cycles can increase the endometrial thickness and improve pregnancy outcome.
|Condition or disease||Intervention/treatment||Phase|
|Endometrial Thickness Pregnancy Outcome||Drug: HCG (human chorionic gonadotropin)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||HCG Priming for Thin Endometrium in IVF|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||January 2014|
Experimental: HCG priming
Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
Drug: HCG (human chorionic gonadotropin)
150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
- Endometrial thickness [ Time Frame: 14 days after estrogen treatment ]measured by transvaginal ultrasound
- Pregnancy outcome [ Time Frame: 5 weeks after embryotransfer ]Clinical pregnancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01768247
|Thessaloniki, Kalamaria, Greece, 55133|
|Principal Investigator:||Papanikolaou Evangelos, MD||HRG clinical director|